BLUE Stock Plunges on Update
It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and regulatory updates were in focus. Recap of the Week’s ...
BioSpace16h
Trump’s Pharma Tariffs, Another GLP-1 Compounding Lawsuit, Bluebird’s Bailout, More
As FDA seeks to rehire some fired employees, Donald Trump threatens to enact tariffs on pharma companies unless they reshore manufacturing; another lawsuit hits the complex GLP-1 compounding space as ...
Zacks.com on MSN16h
Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA
It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and ...
CAR T-Cell Therapy Market Soars With Groundbreaking Innovations Growing At A CAGR Of 28.5%
The CAR T-cell therapy market size was valued at $2.6 billion in 2022 & is estimated to hit $35.9 billion by 2032, exhibiting a CAGR of 28 ...
Sickle Cell Disease Treatment Market Projected To Witness Substantial Growth, 2025-2032:Amgen Inc, Bayer AG, Novartis AG
Sickle Cell Disease Treatment Market is estimated to be valued at USD 3.20 Bn in 2025 and is expected to reach USD 8.81 Bn by 2032 exhibiting a CAGR of 15.6% Mr. Shah Coherent Market Insights Pvt. Ltd ...